



Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbsilpa.com, Web: www.vbsilpa.com
CIN: L85110KA1987PLC008739

Date: 22nd September, 2022

Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

National Stock Exchange of India Limited
Exchange Plaza, 05th Floor,
Plot No: C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400051

Sub: Intimation U/R 30 of the SEBI (LODR) Regulations 2015- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Dear Sir / Madam,

Shilpa Medicare Limited, Analytical Services Division, Nacharam, Hyderabad, Telangana has received US FDA clearance (EIR) for the facility

This is to inform you that the Company's Analytical Services Division situated at Nacharam, Hyderabad, Telangana has received US FDA clearance (EIR) for the inspection performed during 26 Apr 2022 to 29 Apr 2022.

This is the first US FDA inspection of this facility. The facility is identified as testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited (Parent Organization) and its agreed parties. The FDA clearance on the facility will enable the company to test and release batches into US from this facility. This facility, after appropriate submissions, can also be used for testing and releasing batches into Europe and other markets of the world.

The facility is involved in analytical testing of drug products (Release & Stability), drug substances, raw materials & packing materials. It is also engaged in analytical method validations, method transfers and conduct of other miscellaneous analytical studies.

This is for your information and doing the needful.

For **SHILPA MEDICARE LIMITED**

Ritu Tiwary
Company Secretary & Compliance Officer